PDC
lung cancer
line Pharma
anti-PD
cancer patients thanks
Europe
BN
exclusive cell line of Plasmacytoid Dendritic Cells
therapeutic vaccine candidate
cell therapies
leading candidate
Globocan
ground-breaking therapeutic vaccine platform
strong anti-tumour immunity
unmet therapeutic needs
leading cause of deaths
expected market growth
attractive market segment opportunity
cure
unprecedented hope
health economy sustainability
immunotherapies
costly process
revolution of immuno-oncology
novel paradigm
economical burden
high priority
clinical proof of concept
additional toxicity
total costs
response rate
year
path
people
innovation project
IMS
barriers